Literature DB >> 24700708

Development and validation of a recurrent Clostridium difficile risk-prediction model.

Marya D Zilberberg1, Kimberly Reske, Margaret Olsen, Yan Yan, Erik R Dubberke.   

Abstract

BACKGROUND: Recurrent Clostridium difficile infection (rCDI) affects 10% to 25% of patients with initial CDI (iCDI). Initiation of new therapies that reduce recurrences rests on identifying patients at high risk for rCDI at iCDI onset.
OBJECTIVE: To develop a predictive model for rCDI based on factors present at iCDI onset.
DESIGN: Retrospective cohort study.
SETTING: Large urban academic medical center. PATIENTS: All adult patients with an inpatient iCDI from January 1, 2003 to December 31, 2009. INTERVENTION: None. MEASUREMENTS: Positive toxin assay for C difficile with no C difficile infection in the previous 60 days constituted iCDI. Repeat positive toxin within 42 days of stopping iCDI treatment defined rCDI. Three demographic, 13 chronic, and 12 acute disease characteristics, and 7 processes of care prior to or at the onset of iCDI, were assessed for association with rCDI. A logistic regression model to identify predictors for rCDI was developed and cross-validated.
RESULTS: Among the 4196 patients enrolled, 425 (10.1%) developed rCDI. Six factors (case status as community-onset healthcare-associated, ≥2 hospitalizations in the prior 60 days, new gastric acid suppression, fluoroquinolone and high-risk antibiotic use at the onset of iCDI, age) predicted rCDI in multivariate analyses, whereas intensive care unit stay appeared protective. The model achieved moderate discrimination (C statistic 0.643) and calibration (Brier score 0.089). Its negative predictive value was 90% or higher across a wide range of risk.
CONCLUSIONS: Among patients hospitalized with rCDI, multiple factors present at the onset of iCDI increased the risk for rCDI. Recognizing patients at high-risk for rCDI can help clinicians tailor early treatment and prevention.
© 2014 Society of Hospital Medicine.

Entities:  

Mesh:

Year:  2014        PMID: 24700708     DOI: 10.1002/jhm.2189

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  17 in total

Review 1.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

2.  Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in Clostridium difficile Infection: a Retrospective Cohort Study.

Authors:  Julia Origüen; María Ángeles Orellana; Mario Fernández-Ruiz; Laura Corbella; Rafael San Juan; María Ruiz-Ruigómez; Francisco López-Medrano; Manuel Lizasoain; Tamara Ruiz-Merlo; Guillermo Maestro-de la Calle; Patricia Parra; Jennifer Villa; Rafael Delgado; José María Aguado
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

3.  Prediction of Recurrent Clostridium Difficile Infection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System.

Authors:  Gabriel J Escobar; Jennifer M Baker; Patricia Kipnis; John D Greene; T Christopher Mast; Swati B Gupta; Nicole Cossrow; Vinay Mehta; Vincent Liu; Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2017-08-24       Impact factor: 3.254

Review 4.  Clostridium difficile infection.

Authors:  Wiep Klaas Smits; Dena Lyras; D Borden Lacy; Mark H Wilcox; Ed J Kuijper
Journal:  Nat Rev Dis Primers       Date:  2016-04-07       Impact factor: 52.329

5.  Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans.

Authors:  Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei
Journal:  Pharmacotherapy       Date:  2018-02-22       Impact factor: 4.705

6.  Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials.

Authors:  James Baggs; Kimberly Yousey-Hindes; Elizabeth Dodds Ashley; James Meek; Ghinwa Dumyati; Jessica Cohen; Matthew E Wise; L Clifford McDonald; Fernanda C Lessa
Journal:  Vaccine       Date:  2015-10-09       Impact factor: 3.641

7.  Characterizing Risk Factors for Clostridioides difficile Infection among Hospitalized Patients with Community-Acquired Pneumonia.

Authors:  Caroline C Jozefczyk; W Justin Moore; Paul R Yarnold; Nathaniel J Rhodes; Karolina Harkabuz; Robert Maxwell; Sarah H Sutton; Christina Silkaitis; Chao Qi; Richard G Wunderink; Teresa R Zembower
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

8.  Recurrent Clostridium difficile infection among Medicare patients in nursing homes: A population-based cohort study.

Authors:  Marya D Zilberberg; Andrew F Shorr; William M Jesdale; Jennifer Tjia; Kate Lapane
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 9.  The prognostic value of toxin B and binary toxin in Clostridioides difficile infection.

Authors:  Salvador López-Cárdenas; Eva Torres-Martos; Juan Mora-Delgado; Juan Manuel Sánchez-Calvo; Marta Santos-Peña; Ángel Zapata López; María Dolores López-Prieto; Salvador Pérez-Cortés; Juan Carlos Alados
Journal:  Gut Microbes       Date:  2021-03-04

10.  National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014.

Authors:  Kelly R Reveles; Kenneth A Lawson; Eric M Mortensen; Mary Jo V Pugh; Jim M Koeller; Jacqueline R Argamany; Christopher R Frei
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.